NEW YORK, Sept. 30, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today is presenting data describing the tumor microenvironment and immunogenicity of Toca
Growth Capitalist (https://growthcapitalist.com/2018/09/tocagen-presents-preliminary-data-from-toca-6-trial-supportive-of-immune-activation-in-patients-with-advanced-solid-tumors-at-cri-cimt-eati-aacr-international-cancer-immunotherapy-conference/)
NEW YORK, Sept. 30, 2018 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today is presenting data describing the tumor microenvironment and immunogenicity of Toca